Pasteurellosis kills 30%~40% of the world's goat and sheep populations, which leads to chronic infections and death.  

STVac is an Intranasal Spray Vaccine wholly developed by Malaysian scientists from Universiti Putra Malaysia (UPM) for protecting small ruminants such as goats and sheep against the respiratory diseases Mannheimia Haemolytica (also known as pneumonic pasteurellosis).

Effective to reduce
mortality rate

STVac Name.png
Untitled(1).png
Hexagon.png

STVAC USES
RECOMBINANT

TECHNOLOGY

THE DISEASE
IS COMMON IN
GOATS AND SHEEP
POPULATIONS
WORLDWIDE,
LEADING TO
30% - 40% DEATHS

Prof&Prof.png
 
Learn more about STVac
 

Features

STVac is a recombinant inactivated bacterial vaccine produced in E. coli bacteria (as production host) that carries specific outer membrane protein (OMP 31) of M. haemolytica strain A7.

01

Vaccination via injection – stress to animals, high labour cost, time consuming.

04

98% effective to reduce mortality rate

07

Minimal animal handling - no stress to animal and handlers

02

Vaccine delivery via intranasal route which enhance both local and systemic immunities

05

Quick vaccine delivery

08

Pain free, no local reaction and preserve meat quality

03

Competitive price, ambient storage and extended product shelf life

06

Minimal training for handling vaccination

09

Zero withdrawal period for vaccine to clear from the animal's body

 

Facility

Our facility is located at MTDC UPM Serdang, and has the capacity to produce vaccines for 30,000,000 animals a year. 

The GMP production cleanroom consists of main production areas which are Seed Room, Fermentation Room and Purification and Filling Room, while the support production areas are Solution Preparation Room and Washing Room.

 

The cleanroom is designed to comply with GMP guidelines for manufacturing of non-sterile intranasal animal vaccine in cleanroom grade D and C. The finished products which are filled and capped will be further sealed, labelled and packed in carton box in the Packaging Room, which is a Controlled Non-Classified (CNC) grade area.

30,000,000

Current Doses Production Capacity 

WORLD FIRST

GMP

BIONEXUS

Intranasal Vaccine Production Facility for small ruminant

Hi tech International Standard GMP Facility

A Bionexus Status Company

 

Team

1 Stand Finale.png

Professor Dr. Mohd Zamri Saad

Inventor & Technical Advisor

8 Stand Finale.png

YBhg Tan Sri Dr Mohd Daud Bakar

Independent Non-Executive Chairman

11 Stand Finale.png

Noor Shazreena Ishak

Chief Executive Officer

2 Stand Finale.png

Seleman Arip

Founder & Advisor

2.2 Billion

Goats and Sheep Worldwide

US$ 42 Million

Vaccine Contract Secured

US$ 29 Billion

Global Market Value

We are looking for partners worldwide. Send us your interest.

 

The GMP production cleanroom consists of main production areas which are Seed Room, Fermentation Room and Purification and Filling Room, while the support production areas are Solution Preparation Room and Washing Room.

 

The cleanroom is designed to comply with GMP guidelines for manufacturing of non-sterile intranasal animal vaccine in cleanroom grade D and C. The finished products which are filled and capped will be further sealed, labelled and packed in carton box in the Packaging Room, which is a Controlled Non-Classified (CNC) grade area.